Ongoing Disclosure Notice

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Third Age Health Services Limited
Date this disclosure made:22 September 2021
Date of last disclosure: 11 February 2021
Director or senior manager giving disclosure
Full name(s):
Campbell Joseph Patterson
Name of listed issuer:
Third Age Health Services Limited
Name of related body corporate (if applicable):
N/A
Position held in listed issuer:
Senior Manager
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products: Ordinary Shares
Nature of the affected relevant interest(s):
Disposal of 250 Ordinary Shares held
as registered and beneficial owner
For that relevant interest-
Number held in class before acquisition or disposal:
20,250
Number held in class after acquisition or disposal:
20,000
Current registered holder(s):
(1) 250 Ordinary Shares held as
registered and beneficial owner;
(2) 20,000 Ordinary Shares held by
XZS Holdings Limited in its capacity
as an asset holding company
associated with Campbell Patterson
Registered holder(s) once transfers are registered:
20,000 Ordinary Shares held by XZS
Holdings Limited in its capacity as an
asset holding company associated
with Campbell Patterson
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
N/A
Class of underlying financial products:
N/A
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
N/A
A statement as to whether the derivative is cash settled or physically settled:
N/A
Maturity date of the derivative (if any):
N/A
Expiry date of the derivative(if any):
N/A
The price specified in the terms of the derivative (if any):
N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
N/A
For that derivative,-
Parties to the derivative:
N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
N/A
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
Details of transactions requiring disclosure-
Date of transaction:21 September 2021
Nature of transaction:
1
Name of any other party or parties to the transaction (if known):Not known
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
Sold at an average price of $2.48 per
share. Total $620.
Number of financial products to which the transaction related:
250 Ordinary Shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:Yes
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
No
Date of the prior written clearance (if any):
N/A
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:22 September 2021

---

22 September 2021

Third Age Health Services Limited (NZX: TAH) (Company) has been advised of the sale of 250
ordinary shares by a senior manager of the Company who accordingly has issued the
attached Ongoing Disclosure Notice.

The Company advises that this trade took place during the current black-out (closed) period
which applies 30 days prior to TAH ’s half year balance date (30 September), until the first
trading day after the half year results are released to the NZX.

The trade was unwittingly initiated without seeking prior written approval in accordance
with the Company’s Financial Products Trading Policy. Given the black-out period applies,
approval was not given.

This is considered a one off breach of Company policy but to remedy the situation the
company has re issued to all Directors and senior management the Company’s Financial
Products Trading Policy and Guidelines reaffirming the requirements of the policy.

The company is currently up to date with its continuous disclosure requirements.



Bevan Walsh
Chairperson